{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:46:34Z","timestamp":1768005994300,"version":"3.49.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100017540","name":"NHLBI Division of Intramural Research","doi-asserted-by":"publisher","award":["K23HL164901"],"award-info":[{"award-number":["K23HL164901"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","award":["K23HL164901"],"award-info":[{"award-number":["K23HL164901"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The clinical utility of pulmonary hypertension (PH) risk scores in non-group 1 PH with pulmonary vascular disease (PVD) remains unresolved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We utilized the prospective multicenter PVDOMICS cohort with group 2, 3, 4 or 5 PH-related PVD and calculated group 1 PH risk scores (REVEAL 2.0, REVEAL Lite 2, French registry score and COMPERA 2). The c-statistic to predict death was compared separately in (i) pre-capillary PH groups 3\/4\/5, and (ii) combined post- and pre-capillary PH group 2. Exercise right heart catheterization reserve, ventricular interdependence and right ventricular\u2013pulmonary artery (RV-PA) coupling were compared across risk categories. Among 449 individuals with group 3\/4\/5 PH, the REVEAL 2.0 risk score had the highest c-statistic for predicting death (0.699, 95% confidence interval [CI] 0.660\u20130.737, p\u2009&amp;lt;\u20090.0001) with comparable performance using the simpler REVEAL Lite 2 score (0.695, 95% CI 0.656\u20130.734, p\u2009&amp;lt;\u20090.0001). The French and COMPERA 2 risk scores were also predictive of mortality, but performance of both was statistically inferior to REVEAL 2.0 (c-statistic difference\u2009\u22120.072, 95% CI \u22120.123 to \u22120.020, p\u2009=\u20090.006, and\u2009\u22120.043, 95% CI \u22120.067 to \u22120.018, p\u2009=\u20090.0007, respectively). RV function and RV-PA coupling measures were prognostic in isolation, but did not add incremental value to REVEAL (p\u2009&amp;gt;\u20090.50 for all). Findings were similar in patients with group 2 PH (n\u2009=\u2009239). Stratification by the REVEAL Lite 2 score non-invasively identified non-group 1 PH with more advanced PVD with worse exercise capacity, RV-PA uncoupling, ventricular interdependence and impaired cardiac output reserve (p\u2009&amp;lt;\u20090.05 for all).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-invasive REVEAL risk predicts mortality in non-group 1 PH without incremental prognostic value from detailed RV function or RV-PA coupling assessment. Baseline REVEAL Lite 2 risk stratification non-invasively identifies greater pulmonary vascular dysfunction and right heart-related exercise limitation, which may help guide patient selection for targeted pulmonary vascular therapies in non-group 1 PH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3396","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T09:08:11Z","timestamp":1721984891000},"page":"2323-2336","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-Invasive Prediction of Pulmonary Vascular Disease-Related Exercise Intolerance and Survival in Non-Group 1 Pulmonary Hypertension"],"prefix":"10.1093","volume":"26","author":[{"given":"Yogesh N.V.","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Dubrock","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Johns Hopkins University , Baltimore, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Hemnes","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Horn","sequence":"additional","affiliation":[{"name":"Perkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane A.","family":"Leopold","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Rischard","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona , Tucson, AZ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika B.","family":"Rosenzweig","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Medicine, Columbia University , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas S.","family":"Hill","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serpil C.","family":"Erzurum","sequence":"additional","affiliation":[{"name":"Lerner Research Institute, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald J.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Mathai","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Johns Hopkins University , Baltimore, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Johns Hopkins University , Baltimore, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Frantz","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"and the PVDOMICS Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"2026010913045369800_ejhf3396-bib-0001","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"2026010913045369800_ejhf3396-bib-0002","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913045369800_ejhf3396-bib-0003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"2026010913045369800_ejhf3396-bib-0004","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"2026010913045369800_ejhf3396-bib-0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"2026010913045369800_ejhf3396-bib-0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: A refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"2026010913045369800_ejhf3396-bib-0007","article-title":"Comparison of contemporary risk scores in all groups of pulmonary hypertension\u00a0\u2013\u00a0a Pulmonary Vascular Research Institute GoDeep meta-registry analysis","author":"Yogeswaran","journal-title":"Chest"},{"key":"2026010913045369800_ejhf3396-bib-0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02004-2018","article-title":"Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"2026010913045369800_ejhf3396-bib-0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.healun.2018.02.015","article-title":"REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat","volume":"37","author":"Benza","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026010913045369800_ejhf3396-bib-0010","article-title":"Validation of the tricuspid annular plane systolic excursion\/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension","volume":"12","author":"Tello","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026010913045369800_ejhf3396-bib-0011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijcard.2018.01.053","article-title":"Relevance of the TAPSE\/PASP ratio in pulmonary arterial hypertension","volume":"266","author":"Tello","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026010913045369800_ejhf3396-bib-0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.201906-1195LE","article-title":"Evaluation and prognostic relevance of right ventricular-arterial coupling in pulmonary hypertension","volume":"201","author":"Richter","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913045369800_ejhf3396-bib-0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ehjci\/jeaa285","article-title":"Pressure-volume loop validation of TAPSE\/PASP for right ventricular arterial coupling in heart failure with pulmonary hypertension","volume":"22","author":"Schmeisser","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026010913045369800_ejhf3396-bib-0014","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2022.05.038","article-title":"Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease","volume":"80","author":"Hemnes","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913045369800_ejhf3396-bib-0015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCRESAHA.117.311737","article-title":"PVDOMICS: A multi-center study to improve understanding of pulmonary vascular disease through phenomics","volume":"121","author":"Hemnes","year":"2017","journal-title":"Circ Res"},{"key":"2026010913045369800_ejhf3396-bib-0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006363","article-title":"Comprehensive diagnostic evaluation of cardiovascular physiology in patients with pulmonary vascular disease: Insights from the PVDOMICS program","volume":"13","author":"Tang","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026010913045369800_ejhf3396-bib-0017","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","article-title":"The role of the pericardium in heart failure: Implications for pathophysiology and treatment","volume":"7","author":"Borlaug","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913045369800_ejhf3396-bib-0018","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: Pathophysiologic implications","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913045369800_ejhf3396-bib-0019","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913045369800_ejhf3396-bib-0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026010913045369800_ejhf3396-bib-0021","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/ehjci\/jeab065","article-title":"Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: The PVDOMICS experience","volume":"23","author":"Jellis","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026010913045369800_ejhf3396-bib-0022","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","article-title":"The \u03b2-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction","volume":"124","author":"Reddy","year":"2019","journal-title":"Circ Res"},{"key":"2026010913045369800_ejhf3396-bib-0023","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026010913045369800_ejhf3396-bib-0024","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.2015.11082","article-title":"Evaluating discrimination of risk prediction models: The C statistic","volume":"314","author":"Pencina","year":"2015","journal-title":"JAMA"},{"key":"2026010913045369800_ejhf3396-bib-0025","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913045369800_ejhf3396-bib-0026","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913045369800_ejhf3396-bib-0027","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chest.2022.09.007","article-title":"Inhaled treprostinil dosage in pulmonary hypertension associated with interstitial lung disease and its effects on clinical outcomes","volume":"163","author":"Nathan","year":"2023","journal-title":"Chest"},{"key":"2026010913045369800_ejhf3396-bib-0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2026010913045369800_ejhf3396-bib-0029","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): A multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study","volume":"10","author":"Ja\u00efs","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026010913045369800_ejhf3396-bib-0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-2600(22)00171-0","article-title":"Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): An open-label, randomised controlled trial","volume":"10","author":"Kawakami","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026010913045369800_ejhf3396-bib-0031","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: The CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"2026010913045369800_ejhf3396-bib-0032","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: Results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2026010913045369800_ejhf3396-bib-0033","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2019.04.019","article-title":"Hemodynamic effects of weight loss in obesity: A systematic review and meta-analysis","volume":"7","author":"Reddy","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913045369800_ejhf3396-bib-0034","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026010913045369800_ejhf3396-bib-0035","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(23)00923-6","article-title":"Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): A randomised clinical trial","volume":"401","author":"Brugts","year":"2023","journal-title":"Lancet"},{"key":"2026010913045369800_ejhf3396-bib-0036","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Effect of dapagliflozin on right heart-pulmonary vascular interaction in heart failure with preserved ejection fraction","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026010913045369800_ejhf3396-bib-0037","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ejhf.3236","article-title":"A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function","volume":"26","author":"Ameri","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913045369800_ejhf3396-bib-0038","article-title":"Relevance of echocardiography-derived phenotyping in pulmonary arterial hypertension patients treated with initial oral combination therapy","author":"Badagliacca","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/11\/2323\/65507894\/eurjhf_26_11_2323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/11\/2323\/65507894\/eurjhf_26_11_2323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:05:40Z","timestamp":1767981940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/11\/2323\/8328639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,26]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3396","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}